Hypoglycaemia Fundamentals
Definition
Blood glucose <4.0 mmol/L (<72 mg/dL) in patients with diabetes. Some guidelines define the threshold as <3.9 mmol/L. In non-diabetic individuals, hypoglycaemia is defined by Whipple's Triad: low glucose + symptoms + resolution with glucose.
Level Classification (ADA/ISPAD)
Level 1 — Alert
<3.9 mmol/L
(<70 mg/dL)
Alert value — requires self-treatment with fast-acting carbohydrate. Does not necessarily indicate clinically significant hypoglycaemia.
Level 2 — Clinically Significant
<3.0 mmol/L
(<54 mg/dL)
Clinically significant hypoglycaemia. Requires immediate treatment. Associated with serious cognitive and physiological effects.
Level 3 — Severe
Any glucose
with severe cognitive impairment
Severe cognitive impairment (confusion, unconsciousness, seizure) requiring assistance from another person. Medical emergency.
Symptoms
Autonomic Symptoms (Adrenaline-Driven)
Earlier warning signs — triggered by catecholamine release
- Tremor / shakiness
- Diaphoresis (sweating)
- Palpitations / tachycardia
- Anxiety / feeling of dread
- Hunger / nausea
- Pallor
- Paraesthesia (tingling lips)
Neuroglycopenic Symptoms (Brain Glucose Deficient)
Later, more dangerous signs — inadequate CNS glucose
- Confusion / cognitive impairment
- Slurred speech
- Blurred / double vision
- Difficulty concentrating
- Focal neurological deficits (stroke mimic)
- Seizure
- Loss of consciousness / coma
🌞 Counterregulatory Hormones
| Hormone | Source | Effect |
|---|---|---|
| Glucagon | Pancreatic alpha cells | Stimulates hepatic glycogenolysis & gluconeogenesis |
| Adrenaline | Adrenal medulla | Glycogenolysis, lipolysis; triggers autonomic symptoms |
| Cortisol | Adrenal cortex | Gluconeogenesis, reduces peripheral glucose uptake |
| Growth Hormone | Anterior pituitary | Anti-insulin effects, promotes lipolysis |
Important: Impaired Response in Longstanding T1DM
Glucagon response is lost early in T1DM (within 5 years). Adrenaline response diminishes later — leading to hypoglycaemia unawareness, where patients lose autonomic warning symptoms.
🌙 Special Situations
Hypoglycaemia Unawareness
- Loss of autonomic warning symptoms
- Patient does not recognise hypoglycaemia until neuroglycopenic
- Higher risk of Level 2 and Level 3 events
- Caused by recurrent hypoglycaemia lowering the glycaemic threshold for counterregulation
- Management: relax glucose targets, use CGM with alarms, consider DAFNE education programme
Nocturnal Hypoglycaemia
- Often undetected during sleep
- Somogyi Effect: rebound hyperglycaemia next morning due to counterregulatory response
- Suspect if: nightmares, morning headaches, high fasting glucose despite evening insulin
- CGM is gold standard for detection
Causes & Risk Factors
💉 Insulin-Related Causes
| Cause | Mechanism / Notes |
|---|---|
| Excess insulin dose | Injection error, incorrect calculation |
| Wrong insulin type | High Risk Mix-up e.g. Humulin M3 (premix) vs Humulin S (short-acting). Always double-check |
| Timing mismatch | Rapid-acting insulin given without subsequent meal |
| Accidental double dose | Patient or carer administered second dose — common cause in hospital |
| IM injection | Faster absorption than SC — especially in thin patients or using long needles |
| Lipohypertrophy | Variable absorption from affected sites — erratic glucose control |
| Exercise without adjustment | Increased insulin sensitivity; delayed effect up to 24h post-exercise |
💊 Sulphonylurea-Related
Most Dangerous Cause of Prolonged Hypoglycaemia
Sulphonylureas (e.g., glibenclamide, glipizide, gliclazide) stimulate insulin secretion regardless of glucose level. Hypoglycaemia may be prolonged (hours–days) requiring continuous dextrose infusion and hospital admission.
| Factor | Detail |
|---|---|
| Prolonged action | Glibenclamide (half-life up to 45h) — avoid in elderly |
| Renal impairment | Reduced clearance → accumulation → severe prolonged hypoglycaemia |
| Erratic eating | Missed meals with full sulphonylurea effect |
| Drug interactions | Fluconazole, fibrates, NSAIDs potentiate sulphonylurea effect |
| Alcohol | Inhibits hepatic gluconeogenesis — synergistic risk |
🏥 Hospital-Specific Risks
NPO / Fasting Patients on Insulin
- Insulin not withheld or adjusted before procedure
- Patient taken to theatre late without interim glucose
- Ensure VRIII (variable rate insulin infusion) or basal-bolus adjustment protocol followed
- Check glucose pre-op and every 1–2h intra-op
Enteral Feeding & Insulin
- Feed interruption while insulin (bolus or infusion) continues running
- Nasogastric tube dislodged or blocked
- Feed rate reduced without adjusting insulin
- Check glucose at least every 4–6h in enterally-fed patients on insulin
Steroid-Induced Hyperglycaemia
- High-dose steroids cause hyperglycaemia → insulin prescribed
- Steroids tapered or stopped → hyperglycaemia resolves → insulin dose not reduced
- Review insulin at every steroid dose change
- If Dexamethasone given once daily (usually morning), glucose peaks in afternoon
Discharge Without Dose Adjustment
- Patient admitted for poor oral intake — insulin increased
- Discharged on increased dose without review
- Always reconcile insulin dose at discharge against usual home dose
⚠ High-Risk Patient Groups
| Group | Risk Factor | Action |
|---|---|---|
| Elderly patients | Impaired counterregulation, renal impairment, polypharmacy, reduced hypoglycaemia awareness | Relaxed targets (HbA1c 7.5–8%), avoid glibenclamide, consider CGM |
| Longstanding T1DM | Hypoglycaemia unawareness, absent glucagon response | Relaxed targets, CGM with low alarms, hypoglycaemia awareness training |
| Tight glycaemic control | Narrowed margin; intensive insulin regimens | Structured education (DAFNE), CGM, frequent SMBG |
| Chronic Kidney Disease | Reduced insulin clearance, reduced gluconeogenesis, reduced renal glucose release | Reduce insulin doses (eGFR <30), avoid sulphonylureas (except gliquidone), monitor frequently |
| Liver disease (cirrhosis) | Reduced glycogen storage, impaired gluconeogenesis | Frequent monitoring, reduce insulin doses, nutritional support |
| Alcohol misuse | Suppresses hepatic gluconeogenesis; masked by symptoms | Never attribute confusion to intoxication without checking glucose first |
🌍 GCC Context: Ramadan Fasting Hypoglycaemia
Ramadan fasting (typically 12–16 hours) significantly alters meal timing and carbohydrate distribution. Patients on insulin or sulphonylureas are at high risk of hypoglycaemia at pre-iftar (end of fast) and post-suhoor periods. Pre-Ramadan structured assessment and dose adjustment is essential. Break fast immediately if glucose <4.0 mmol/L. See Tab 4 for management protocols.
Treatment Protocols
THE RULE OF 15
For mild-to-moderate hypoglycaemia in conscious patients who can swallow
15g
Fast-acting carbohydrate
→
15 min
Wait and recheck BG
→
Repeat
If BG still <4.0 mmol/L
→
Follow up
Long-acting carbohydrate
🌭 15g Carbohydrate Options
Community / Home
- ● 150–200 mL fruit juice (no added sugar variety)
- ● 150–200 mL regular (non-diet) cola
- ● 3–4 glucose tablets
- ● 5 jelly babies
- ● 1 tablespoon of sugar/honey dissolved in water
Hospital
- ● GlucoGel (40% dextrose oral gel) — 2 tubes = ~20g glucose; can be applied buccally if slightly impaired swallow but some protection reflex present
- ● Glucose tablets (Dextro Energy)
- ● 200 mL Lucozade Original
- ● 200 mL orange juice
Follow-Up: Long-Acting Carbohydrate
After BG rises >4.0 mmol/L — give a long-acting carbohydrate snack: 2 biscuits, 1 slice bread/toast, a sandwich, or next meal if due within 30 minutes. This prevents recurrence as the fast-acting sugar effect wanes.
🚨 Severe Hypoglycaemia — Unconscious / Unable to Swallow
IV Dextrose (First Choice in Hospital)
- 75–100 mL of 20% glucose IV (preferred concentration)
- Avoid 50% dextrose — highly hypertonic, severe vein irritant, risk of thrombophlebitis and extravasation injury
- Administer over 10–15 minutes via large vein
- Recheck glucose 15 minutes post-infusion
- Repeat if glucose <4.0 mmol/L
- If no IV access: glucagon IM
Glucagon 1mg IM / SC
- Use when IV access unavailable
- Stimulates hepatic glycogenolysis — requires intact glycogen stores
- NOT reliable in sulphonylurea hypoglycaemia — limited glycogen stores, stimulates endogenous insulin
- NOT effective in malnourished patients, liver disease, or after prolonged fasting
- May cause nausea/vomiting on recovery
- Available as: GlucaGen HypoKit (1mg vial)
- Patient may take 10–15 min to respond
DO NOT Give Anything by Mouth to an Unconscious Patient
Risk of aspiration pneumonia. Establish IV access. Place in recovery position if airway at risk. Call for urgent medical assistance.
💉 Sulphonylurea-Induced Prolonged Hypoglycaemia
Management Protocol
- Admit to hospital — observation for minimum 24h (longer for long-acting agents)
- Continuous IV glucose infusion (10% dextrose) — titrate to maintain BG 6–10 mmol/L
- Octreotide (somatostatin analogue) — suppresses ongoing sulphonylurea-driven insulin secretion; 50–100 mcg SC/IV TID
- Activated charcoal if within 1h of ingestion (overdose scenario)
- Notify endocrinology/diabetology team
- Review renal function (dose reduction/agent change on discharge)
✅ Post-Recovery Actions
1
Do not omit next meal
Ensure patient eats regular meal within 30–60 min of recovery to stabilise glucose
2
Continue glucose monitoring
Check every 30–60 min until glucose stable >5.0 mmol/L for 2 readings
3
Notify diabetology team
All Level 2 and Level 3 episodes require senior review. Complete incident report for all in-hospital hypoglycaemia.
4
Review causative medication
Insulin dose adjustment, sulphonylurea review, timing correction, patient education
5
Insulin pump (CSII) patients
Suspend pump during active hypoglycaemia. Do not resume until glucose >5.0 mmol/L and patient has eaten. Notify pump team for basal rate review.
6
Document fully
Time of event, glucose value, symptoms, treatment given, response time, post-treatment glucose, actions taken, patient education provided
Prevention & Sick Day Rules
🛠 Prevention Strategies
Patient & Carer Education
- Recognise early autonomic warning symptoms
- Always carry fast-acting glucose (glucose tablets, juice)
- Inform family/colleagues of hypoglycaemia recognition and glucagon use
- Medical ID bracelet / diabetes alert card
- DAFNE (Dose Adjustment For Normal Eating) programme
Monitoring & Technology
- SMBG (Self-monitoring blood glucose): before meals, 2h post-meal, bedtime, before driving
- CGM with low glucose alarms (<4.0 mmol/L threshold)
- Hybrid closed-loop systems reduce nocturnal hypoglycaemia significantly
- Check glucose before exercise and adjust carbohydrate/insulin
Medication Review
- Avoid glibenclamide in elderly and those with CKD
- Review insulin doses at every clinic visit
- Rotate injection sites — prevent lipohypertrophy
- Consistent injection technique and site
- SGLT2 inhibitors and GLP-1 agonists have low intrinsic hypoglycaemia risk
🤪 Sick Day Rules
NEVER Stop Insulin in Type 1 Diabetes During Illness
Even if not eating, T1DM patients MUST continue insulin to prevent diabetic ketoacidosis (DKA). Illness typically increases insulin requirements due to counterregulatory hormone release.
Sick Day Rule Actions (T1DM)
- Continue basal insulin — may need to increase
- Correct high glucose with additional rapid-acting insulin
- Check blood ketones every 2–4h if glucose >14 mmol/L
- Maintain fluid intake (water, sugar-free fluids)
- If eating reduced: replace meals with carbohydrate-containing drinks
- Contact diabetologist / diabetes specialist nurse if ketones >1.5 mmol/L
- Seek emergency care if vomiting, unable to keep fluids down
Sick Day Rules (T2DM)
- Hold SGLT2 inhibitors during illness (DKA risk, dehydration)
- Hold metformin if vomiting/dehydration (lactic acidosis risk)
- Sulphonylureas: omit if not eating
- Continue basal insulin at reduced dose if eating less
- Monitor glucose more frequently
🌬 Ramadan Fasting — Diabetes Management
Islamic Ruling on Breaking Fast for Medical Necessity
Islamic scholars unanimously permit (and many consider obligatory) breaking the fast if blood glucose falls below 4.0 mmol/L, rises above 16.7 mmol/L, or if the patient feels unwell. Illness negates the obligation to fast (Quran 2:185). Medical teams should reinforce this ruling.
Pre-Ramadan Assessment (4–6 Weeks Before)
- Classify risk: very high, high, moderate, low
- HbA1c, renal function, CGM/SMBG review
- Structured education on dose adjustments, glucose targets, when to break fast
- Discuss with patient their intention and ability to fast safely
- Review all diabetes medications
Medication Adjustments for Ramadan
- Sulphonylureas: Reduce dose or avoid; shift main dose to iftar. Glibenclamide — avoid entirely
- Basal insulin: Reduce by 20–30% and shift timing to post-iftar or pre-suhoor
- Premix insulin: Reduce morning (suhoor) dose; adjust evening (iftar) dose
- SGLT2 inhibitors: Consider holding (dehydration risk, DKA)
- Metformin, DPP-4 inhibitors, GLP-1: Usually safe; adjust timing to iftar
When to Break the Fast — Blood Glucose Thresholds
- Break immediately if glucose <4.0 mmol/L — treat hypoglycaemia first
- Break if glucose <4.0–4.9 mmol/L and in first few hours of fast (likely to worsen)
- Break if glucose >16.7 mmol/L — check ketones, seek medical advice
- Break if feeling unwell, dizzy, or displaying any hypoglycaemia symptoms
- Document and reassess daily during Ramadan
🏥 Hospital Glucose Targets & Peri-Operative Management
Hospital Glucose Targets
- General ward: 6–10 mmol/L (NICE NG17)
- Acceptable range: 4–12 mmol/L (if targets not immediately achievable)
- Critically ill (ITU): 6–10 mmol/L (ADA/AACE joint guidelines)
- Avoid: <4.0 mmol/L or >12 mmol/L for prolonged periods
- Review insulin at every meal round
Peri-Operative Diabetic Patient
- Pre-op fasting glucose check — delay surgery if <4.0 or >12 mmol/L
- T1DM: always use VRIII (variable rate insulin infusion / sliding scale) during prolonged fasting
- T2DM on insulin: VRIII or modified basal-bolus approach depending on local protocol
- T2DM on oral agents: omit morning doses; restart when eating and drinking normally
- Hourly glucose monitoring intra-operatively when on VRIII
- First on operating list preferred to minimise fasting time
CGM, Technology & Nursing Care
🔌 Types of CGM
| Type | Examples | Key Feature |
|---|---|---|
| rtCGM Real-time CGM | Dexcom G6/G7, Medtronic Guardian 3/4 | Continuous automatic reading every 5 min; alarms for high/low; no scan required |
| isCGM Intermittent scan CGM | FreeStyle Libre 2 / Libre 3 | Requires scan (phone/reader) to get reading; Libre 2/3 also has optional alarms; Libre 3 continuous transmission |
How CGM Works
Measures interstitial glucose (not blood glucose directly) via a small sensor wire inserted subcutaneously. There is a 5–10 minute physiological lag between blood glucose and interstitial glucose. Calibration: Dexcom G7 factory-calibrated; Medtronic Guardian requires fingerstick calibration.
↑ Trend Arrows — Clinical Interpretation
| Arrow | Meaning | Nursing Action |
|---|---|---|
| → Horizontal | Stable — changing <1 mmol/L per 15 min | No immediate action unless at threshold |
| ↗ Slight rise | Rising 1–2 mmol/L per 15 min | Monitor; consider pre-meal rapid insulin if appropriate |
| ↑ Rising rapidly | Rising >2 mmol/L per 15 min | Check for missed dose; notify medical team if >12 mmol/L |
| ↘ Slight fall | Falling 1–2 mmol/L per 15 min | Give snack if borderline; increase monitoring frequency |
| ↓ Falling rapidly | Falling >2 mmol/L per 15 min | Act now — treat as hypoglycaemia even if not yet <4.0 mmol/L |
| ↓↓ Very rapid fall | Falling >3 mmol/L per 15 min | Urgent — treat immediately, notify team, prepare IV glucose |
Key Nursing Point: Trending Down
A glucose of 5.2 mmol/L with rapid downward arrows (↓↓) requires immediate treatment. The patient will likely be <4.0 mmol/L within 10–15 minutes. Do not wait for the alarm to trigger.
🎯 Time In Range (TIR) — Clinical Standards
TIR measures the percentage of time glucose is within target range (3.9–10.0 mmol/L / 70–180 mg/dL). Agreed by international consensus (Battelino et al. 2019).
<3.9 mmol/L: Target <4%
<3.0 mmol/L: Target <1%
3.9–10.0: Target >70%
>10.0 mmol/L: Target <25%
| Patient Group | TIR Target | TBR Target | TIR Target (Elderly/High-Risk) |
|---|---|---|---|
| T1DM | >70% | <4% (<3.9), <1% (<3.0) | >50% (relaxed) |
| T2DM on insulin | >70% | <4% | >50% (relaxed) |
| Pregnancy (T1DM) | >70% (3.5–7.8 mmol/L) | <4% | N/A |
| Critically ill | N/A — use point-of-care BG | Avoid <4.0 mmol/L | N/A |
💉 Insulin Pumps (CSII)
Continuous Subcutaneous Insulin Infusion
- Delivers rapid-acting insulin continuously as basal rate (unit/hour, customisable)
- Bolus delivered for meals (calculated by pump wizard using carb ratio, ISF, active insulin)
- Sick day rules: Never leave CSII interrupted for >2 hours without giving subcutaneous injection — risk of DKA rapid onset (no long-acting insulin reservoir)
- Infusion site change every 2–3 days
- Hospital: document pump settings; involve DSN; do not arbitrarily stop pump
Hybrid Closed-Loop (Artificial Pancreas)
- CGM + insulin pump + algorithm communicating automatically
- Algorithm adjusts basal rate in real-time to maintain glucose in range
- Examples: Medtronic MiniMed 780G, Tandem Control-IQ, CamAPS FX
- Significantly reduces nocturnal hypoglycaemia and TBR
- Still requires patient bolus for meals (hybrid, not fully closed)
🏥 Hospital CGM Use — Nursing Guidance
When to Trust CGM vs Capillary Glucose
- If CGM and capillary BG agree within 1.0 mmol/L — use CGM-guided trend arrows with confidence
- If discordant by >1.5 mmol/L — use capillary glucose for treatment decisions
- Always use capillary BG to confirm before treating severe hypoglycaemia (Level 2–3) if time allows
- Discordance common with: rapid glucose change, poor sensor placement, oedema, peripheral shutdown
Sensor Accuracy (MARD)
Mean Absolute Relative Difference (MARD) <10% considered clinically adequate. Dexcom G7: MARD ~8.2%. FreeStyle Libre 3: MARD ~7.9%. Accuracy is lower at extremes of glucose range (hypoglycaemia and hyperglycaemia >20 mmol/L).
GCC Context & Exam Preparation
23.1%
Kuwait — Diabetes Prevalence
19.3%
UAE — Diabetes Prevalence
18.3%
Saudi Arabia — Prevalence
Top 10
GCC globally for T2DM
🌍 GCC-Specific Clinical Considerations
Ramadan & Steroid-Induced Hyperglycaemia
- Patients on dexamethasone (e.g., for multiple myeloma, post-transplant) during Ramadan
- Dexamethasone given post-iftar to minimise fasting hours of hyperglycaemia
- Insulin requirement peaks 6–12h after dexamethasone dose — anticipate and adjust
- Requires daily review and flexible insulin protocols during Ramadan
- Coordinate with haematology/oncology teams
Regulatory Framework — GCC
- DHA (Dubai): Dubai Health Authority — exam and licensing authority for Dubai
- DOH (Abu Dhabi): Department of Health Abu Dhabi — licensing authority
- SCFHS (Saudi Arabia): Saudi Commission for Health Specialties — exam body for Saudi healthcare workers
- All follow international evidence-based guidelines (NICE, ADA, IDF)
- Localised diabetes guidelines for Ramadan: IDF-SACA Ramadan Guidelines
📚 High-Yield Exam Points
| Topic | Key Point to Remember |
|---|---|
| Hypoglycaemia definition | <4.0 mmol/L in diabetics; Level 1 <3.9, Level 2 <3.0, Level 3 = any with severe cognitive impairment |
| Rule of 15 | 15g carbohydrate → 15 min wait → recheck; repeat if still <4.0; always follow with long-acting carb |
| 50% dextrose | Avoid — use 20% dextrose 75–100 mL instead; 50% causes vein damage |
| Glucagon limitations | NOT reliable in sulphonylurea OD, liver disease, malnourishment — limited glycogen stores |
| Sulphonylurea hypoglycaemia | Most dangerous — prolonged; needs octreotide + continuous dextrose infusion + hospital admission |
| Hypoglycaemia unawareness | Loss of autonomic warnings in longstanding T1DM; treated by relaxing targets, CGM, education |
| Somogyi effect | Nocturnal hypoglycaemia → rebound morning hyperglycaemia; diagnose with CGM or 3am glucose check |
| Stroke vs hypoglycaemia | Always check BG before assuming stroke — focal neurology can be neuroglycopenic |
| Insulin in T1DM sick days | NEVER stop insulin in T1DM illness — risk DKA; increase monitoring; check ketones |
| Ramadan — break fast | BG <4.0 mmol/L or >16.7 mmol/L → must break fast; Islam permits this for medical necessity |
| CGM arrows | Rapid fall (↓↓) = treat now even if glucose borderline; do not wait for alarm |
| CSII pump failure | DKA within hours (no long-acting insulin depot); never interrupt CSII >2h without injection |
| Time In Range | Target >70% in 3.9–10 mmol/L; TBR <4% <3.9 mmol/L; <1% <3.0 mmol/L |
MCQ Practice — 10 Questions
Click an option to reveal the answer and explanation.
⚡ Hypoglycaemia Treatment Calculator
Enter patient details to receive a personalised treatment pathway and documentation guide